Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
MR imaging features of spinal schwannomas and meningiomas
Nandy, D
doi:10.1016/S0021-9258(18)90661-7
This product is intended exclusively for qualified researchers operating within approved protocols and appropriate biosafety frameworks
Tirzepatide produced greater A1c reductions than semaglutide in the SURPASS-2 head-to-head trial, making it the stronger option for glycemic control
People with diabetes who are also taking insulin or sulfonylureas would face an additional risk of hypoglycaemia, and such combinations should only ever be considered within a closely supervised clinical trial setting
US$ 20.21
US$ 21.44
US$ 28.12
US$ 24.08
US$ 26.77
US$ 23.61
US$ 24.31
US$ 26.72
US$ 22.68
